Ind-Swift Laboratories Q2 EBITDA rises 4.95 times year on year

Ind-Swift Laboratories Limited reported standalone operating EBITDA, or earnings before interest, tax, depreciation and amortisation, of Rs 42.33 crore for Q2 FY27, up 4.95 times from Rs 8.55 crore a year earlier. Operating income increased 50.15% to Rs 234.89 crore, while the operating EBITDA margin rose to 18.02% from 5.46%.

How did Ind-Swift Laboratories perform in Q2 FY27?

Ind-Swift Laboratories increased Q2 FY27 operating income by 50.15% year on year to Rs 234.89 crore and operating EBITDA by 4.95 times to Rs 42.33 crore. The results cover the quarter ended September 30, 2026, and were announced on October 30, 2026. Profit after tax, or PAT, rose 3.54 times to Rs 31.03 crore from Rs 8.76 crore in Q2 FY26.

Ind-Swift Laboratories reported an operating EBITDA margin of 18.02%, compared with 5.46% in Q2 FY26, a 1,256.01-basis-point increase in its detailed quarterly table. PAT margin rose to 13.21% from 5.60%, an increase of 761.18 basis points. The announcement headline cited a 5.2-times operating EBITDA increase, while the detailed table stated 4.95 times.

What drove Ind-Swift Laboratories’ Q2 margin expansion?

Ind-Swift Laboratories said its earlier transition from active pharmaceutical ingredient, or API, manufacturing to finished dosage formulations, or FDF, and a scale-up in operations improved business mix and margins. Raw-material expense fell to 45.15% of revenue in Q2 FY27 from 49.38% a year earlier, a 423-basis-point reduction alongside the increase in operating EBITDA margin to 18.02%.

Ind-Swift Laboratories also said its contract development and manufacturing organisation, or CDMO, partnerships were contributing more to topline growth. Chairman N.R. Munjal said the shift to FDF and larger operating scale were delivering operating leverage. The announcement does not quantify the separate contribution from CDMO partnerships, product lines or individual markets.

Ind-Swift Laboratories recorded profit growth despite a decline in non-operating other income. Other income fell 35.95% to Rs 7.60 crore, while profit before tax, or PBT, rose 3.6 times to Rs 40.24 crore. Finance cost declined 33.83% to Rs 1.33 crore, which was another reported factor in the quarter’s earnings movement.

How did Ind-Swift Laboratories’ H1 FY27 results compare?

Ind-Swift Laboratories reported H1 FY27 operating income of Rs 420.97 crore, up 35.79% from Rs 310.02 crore in H1 FY26, while operating EBITDA rose 4.45 times to Rs 75.65 crore. The first-half operating EBITDA margin reached 17.97%, compared with 5.47% a year earlier, extending the margin improvement reported in the September quarter.

Ind-Swift Laboratories’ H1 FY27 PAT increased 3.29 times to Rs 55.47 crore, with PAT margin rising to 13.18% from 5.44%. Operating EBITDA margin increased by 1,253.66 basis points over the six-month comparison. Operating-income growth for H1, at 35.79%, was lower than the 50.15% growth reported for Q2 alone, while the H1 operating EBITDA margin of 17.97% was close to Q2’s 18.02%.

Ind-Swift Laboratories also reported sequential growth from Q1 FY27. Q2 operating income was 26.23% above Q1 FY27 operating income of Rs 186.08 crore, and Q2 operating EBITDA was 27.02% above Q1’s Rs 33.32 crore. Operating EBITDA margin rose by 11 basis points from 17.91% in Q1 FY27 to 18.02% in Q2 FY27.

What is Ind-Swift Laboratories planning after Q2 FY27?

Ind-Swift Laboratories said it remains committed to scaling its operations and sustaining profitable growth through its FDF platform. Management cited a net-debt-free balance sheet, the FDF focus and a stronger operating base after Q2 FY27 operating income of Rs 234.89 crore. The October 30 announcement did not provide a future revenue, profit or margin target.

Ind-Swift Laboratories described its formulations model as covering international exports, domestic branded formulations and CDMO partnerships, serving regulated and emerging markets. The company said it has a presence in more than 85 countries and manufacturing facilities with multiple international regulatory accreditations. It also cited formulation research and development infrastructure supporting product development, filings and commercialisation.

Ind-Swift Laboratories said its priorities following its API and contract research and manufacturing services divestment include expanding exports, strengthening CDMO visibility and improving margins. It cited a dossier pipeline and established partnerships, but did not disclose product-launch dates, filing schedules, capital-expenditure amounts or a timetable for those priorities.

Conclusion

Ind-Swift Laboratories combined 50.15% Q2 FY27 operating-income growth with an increase in operating EBITDA margin to 18.02% from 5.46% a year earlier. Operating EBITDA reached Rs 42.33 crore and PAT reached Rs 31.03 crore, while a lower raw-material expense ratio and a 33.83% decline in finance cost accompanied the earnings improvement despite lower other income.

The next measure will be execution of management’s stated plan to scale FDF operations, expand exports and strengthen CDMO visibility. Ind-Swift Laboratories reported H1 FY27 operating EBITDA of Rs 75.65 crore at a 17.97% margin, but the announcement sets no numerical target or scheduled operating milestone for assessing future progress.